Our findings suggest that biologics, like anti-TNF-alpha agents (i.e., adalimumab and infliximab) and IL-6 agents, such as tocilizumab, may effectively prevent recurrences of RPC; however, MMF and IFN-alpha-2a should perhaps be avoided. The gene discussed is IL6; the disease is familial reactive perforating collagenosis.